News
The Augurex team brings together leading scientific, clinical, technical and commercial expertise to ensure that our research translates into advanced diagnostics for improved patient outcomes.
JOINTstat™ (14-3-3η); New Possibilities in RA
Augurex Life Sciences Corp. announces big leaps forward for applications of the JOINTstat™ (14-3-3η) blood test in rheumatoid arthritis (RA). Disease management is quickly moving upstream toward earlier identification and treatment, in some cases even pre-disease, and...
JOINTstat™ cleared for clinical use in Australia by the Therapeutic Goods Administration (TGA)
Augurex is pleased to announce that the JOINTstat™ (14-3-3η) blood test has been cleared for clinical use in Australia by the Therapeutic Goods Administration (TGA). The test is indicated for the diagnosis of rheumatoid arthritis (RA) and the assessment and monitoring...
Augurex Presenting at World Congress on Inflammation
At the 12th World Congress on Inflammation in Boston from August 8-12, Dr. Anthony Marotta will be co-chairing Symposium #29: Biomarkers in Inflammation: Focus on Rheumatoid Arthritis and will be delivering the following two presentations alongside presenter and...
JOINTstat™ – Expanding the Impact
Expanded Use Indications JOINTstat™, a clinically game-changing blood test for Rheumatoid Arthritis (RA), now has expanded use indications in Canada and the EU. This novel test, which measures a protein called 14-3-3η, was first indicated for diagnostic use in RA....
New Testing And Treatment Improves Outlook For Those With Rheumatoid Arthritis
PREVENTION AND TREATMENT If you have been experiencing a prolonged period of pain, tenderness and stiffness around your joints, you should get to a doctor — and make it fast. Please read the full article on the personalhealthnews.ca website here...
JOIN OUR WEBINAR: JOINTstat™ – A New Blood Test for Rheumatoid Arthritis Diagnosis
Canadian Rheumatologist Webinar You are invited to: Introducing JOINTstat™ (14-3-3η): A New Biomechanistic Marker for the Early Diagnosis and Prognosis of Rheumatoid Arthritis Presenter: Walter P. Maksymowych, MD F.R.C.P.(C) Professor and Medical Scientists in the...
JOINTstat™ – Transforming RA Patient Management
LifeLabs Medical Laboratory Services, the country's largest provider of community laboratory services, yesterday announced the Canadian launch of JOINTstat™ (14-3-3η), a biomarker blood test that is providing transformational insights into autoimmune joint damage...
LifeLabs Launches Arthritis Blood Test JOINTstat™ (14-3-3eta) in Canada
TORONTO, ONTARIO and VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 2, 2015) - LifeLabs Medical Laboratory Services ("LifeLabs") announced today the launch of JOINTstat™, a diagnostic blood test for rheumatoid arthritis. The JOINTstat™ blood test is the first test...
New Studies Expand the Large Body of Data on the Important Role of an Arthritis Protein; 14-3-3eta Blood Test
Vancouver, BC – November 5, 2014. Augurex Life Sciences Corp. announces a burgeoning body of data that further reveals the important role of a protein measured in blood, called 14-3-3eta, in rheumatoid arthritis (RA). Ten studies will be presented at the world's...
Exciting Update From the World of BC Biotechnology
When early discoveries are made at universities, they usually require additional research and funding to uncover what the innovation's clinical usefulness will be to patients and physicians. For example, in 2006 researchers at the University of British Columbia (Dr....
Protein Measured by a Blood Test Marks Joint Erosions in Arthritis
At Europe's premier arthritis congress, the European League Against Rheumatism (EULAR) last week in Berlin, researchers presented findings that a protein measurable in blood named 14-3-3η, marks the presence of joint damage in two different forms of arthritis,...
Novel Blood Test Identifies Patients with Early Rheumatoid Arthritis; Findings Reported at the American College of Rheumatology (ACR)
Not unlike cancer, disease outcome can be dramatically improved if RA is caught and treated early. Augurex Life Sciences Corp. reported that in Chicago at the American College of Rheumatology (ACR) Annual Scientific Meeting, world-leading arthritis researchers from...
Augurex Reports Positive Data for RA Blood Test and Drug Target at the Annual European Congress of Rheumatology (EULAR)
Company's novel biomarker and drug target could represent the first personalized medicine in RA promise for future targeted therapy in a multi-factorial disease. Augurex Life Sciences Corp. today reported that in London at the European League Against Rheumatism...
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Home
Products
Science
About
News
Careers
Contact